GlassScriptPhysician profile
Michael D Huber
NPI 1518916162
$1,500.91
in general payments reported to CMS, 2019-2025
21 companies · $181 in 2025
The $181 reported for 2025 was more than what 79% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $168 · 2021: $77.80 · 2022: $220 · 2023: $319 · 2024: $416 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $405.10 | 2019-2025 | Caldolor |
| Tactile Systems Technology INC | $187.03 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $161.52 | 2019-2024 | Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $147.55 | 2021-2024 | Entyvio |
| Abiomed | $109.72 | 2024-2025 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.17 | 2019-2024 | Xifaxan |
| Chiesi USA, INC. | $69.25 | 2020-2022 | |
| Braintree Laboratories, INC. | $67.86 | 2022-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $54.23 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Ardelyx, INC. | $36.16 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $30.02 | 2022-2023 | |
| La Jolla Pharmaceutical Company | $17.17 | 2025 | Giapreza |
| Aimmune Therapeutics, INC. | $15.95 | 2023 | |
| Redhill Biopharma INC. | $14.97 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.95 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.93 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.71 | 2024 | Exparel, Iovera |
| Grifols USA, LLC | $14.62 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.59 | 2019 | |
| Heron Therapeutics, INC. | $13.78 | 2022 | |
| Baudax Bio INC. | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Huber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.